Using IL-1β to treat hepatitis B virus infections
IL-1β as a novel therapeutic agent against hepatitis B virus
This study is exploring a new treatment using a substance called interleukin-1β (IL-1β) to help people with chronic hepatitis B by potentially boosting the immune system to fight the virus better and improve their overall treatment results.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-11001919 on NIH RePORTER |
What this research studies
This research investigates the potential of interleukin-1β (IL-1β) as a new treatment for chronic hepatitis B virus (HBV) infections. The study aims to understand how IL-1β can suppress HBV gene expression, which is crucial for the virus's ability to persist in the body. By targeting specific transcription factors, the research hopes to achieve a 'functional cure' for HBV, potentially leading to the activation of the immune system to eliminate infected liver cells. Patients may benefit from a novel therapeutic approach that could improve treatment outcomes compared to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with chronic hepatitis B virus infections who have not responded adequately to current treatments.
Not a fit: Patients with acute hepatitis B infections or those who have already achieved a functional cure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that may lead to a functional cure for chronic hepatitis B virus infections.
How similar studies have performed: While the use of IL-1β in this context is novel, previous research has shown promise in targeting viral infections with immune-modulating therapies.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Ou, J.-H. James — University of Southern California
- Study coordinator: Ou, J.-H. James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.